Friends! In this video, I'm going to do an AMD stock analysis and talk about the risks and upside potential of AMD stock
1 extracted signal · 1 resolved · 0 still active
The Patient InvestorIndependent analyst profile- Source published
- 05 Aug 2025, 21:47 UTC
- Recorded by Tahlil Plus
- 18 May 2026, 20:23 UTC

AI-generated source summary
The analysis is based on AMD's Q2 2025 financial results. Earnings per share missed estimates at 48 cents adjusted versus 49 cents expected. Revenue beat expectations at $7.69 billion versus $7.42 billion expected. Guidance for the third quarter is strong, expecting sales of $8.7 billion plus or minus $300 million, versus analyst expectations of $8.3 billion. Revenue growth was 32% year-on-year. Non-GAAP gross margins decreased from 53% to 43%. Operating income and earnings per share on a non-GAAP basis also declined year-on-year. The data center business revenue was weak but client and gaming segments showed 69% overall growth. Chip export restrictions to China had a negative impact of $800 million in the June quarter. The speaker said shipments expected to resume waivers potentially being approved. The guidance does not include China revenues. The speaker provided a valuation model with an earnings per share of $3.96 for 2025, 48% growth for 2026 and 20% from 2027 to 2030 with a PE ratio of 30 times implying a $364.59 target.
AI-generated summary based on the source content.
Signal outcomes at a glance
Evaluation CompleteSignals in this source
Evidence and evaluation progress
- Original source published
The analyst published the original source item.
- Source recorded by Tahlil Plus
The public source was preserved as the evidence record for this case.
- Market predictions extracted
1 eligible signal linked to this case.
- Outcome tracking started
Tahlil Plus began monitoring the extracted predictions.
- First prediction resolved
The first evaluable outcome in this case reached a terminal result.
- Case evaluation completed
All evaluable predictions in this case reached terminal outcomes.
The Patient Investor
Platform-wide history, separate from this source evaluation.
Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.
